. Laparoscopic adrenalectomy for malignant disease . Lancet Oncol 2004 ; 5 : 718 – 726 . 40 Dickstein G Shechner C Arad E . Is there a role for low doses of mitotane (o,p’-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol
Search Results
Jonathan R. Strosberg, Gary D. Hammer, and Gerard M. Doherty
Edited by Kerrin G. Robinson
Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson
method of operation. However, this information is important to review postoperatively because it may better identify patients with aggressive pathologic features potentially suitable for adjuvant therapy clinical trials. The Role of Lymphadenectomy
Eric Jonasch
is partial or radical nephrectomy or, in select patients, active surveillance. Further treatment is typically not recommended. “Following nephrectomy, adjuvant therapy for RCC has been an exercise in frustration,” he pointed out. Recent studies
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone
primary surgery, with adjuvant therapy as indicated. For patients not suitable to receive primary surgery, primary treatment recommendations include systemic therapy and/or pelvic radiation therapy (RT) with or without brachytherapy. Systemic therapy is an
Kari E. Hacker, Shitanshu Uppal, and Carolyn Johnston
patients with pathology upgraded to carcinoma were included in analyses. 53 Finally, some gynecologic oncologists recommend completion of surgery after childbearing, because most recurrences are in the contralateral ovary. 56 Adjuvant therapy is
Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani
are perhaps most intriguing, 61 which randomized 1059 patients with stage II or III gastric cancer who underwent D2 surgical resection to either observation or 1 year of oral S-1 adjuvant therapy. S-1 is an orally active combination of tegafur (i
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang
Elson P Propert K . Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma [abstract] . Proc Am Soc Clin Oncol 1996 ; 15 : Abstract 253 . 19 Kavolius JP
Amanda N. Fader
extent of adjuvant therapy, and managing locoregional recurrence. In fact, laparoscopy has become the gold standard treatment of many gynecologic conditions, “both benign and malignant,” reported Dr. Fader. Many studies have shown improved outcomes with
Eric Jonasch
not support the use of adjuvant therapy for RCC in 2015. With the advent of various antiangiogenic agents and mTOR inhibitors, investigators have moved past the cytokine therapy era, he noted. In the upcoming years, Dr. Jonasch predicted, the next wave
Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett
patients—a Dutch colorectal cancer group study . J Clin Oncol 2005 ; 23 : 6199 – 6206 . 94 Tepper JE O’Connell M Niedzwiecki D . Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114 . J
